Evaluating the Need for New Rhinitis Treatment

Completed

• Conditions: Rhinitis

• Registration Number: NCT01875276
• Lead Sponsor: Research in Real-Life Ltd

Brief Summary

The proposed study will evaluate the unmet therapy need in seasonal rhinitis by aiming to answer the following research questions

1. What is the first prescription of the hay-fever season and how many of these patients are on some form of combination therapy?

2. To what extent does initial therapy not meet clinical need (as measured by need for additional medical intervention in terms of consultations and changes in therapy)?

3. Does treatment for allergic rhinitis differ for asthma Vs non-asthma and seasonal Vs perennial patients?

Detailed Description

Allergic rhinitis is a chronic respiratory disease with a major impact on quality of life. In a study looking at the burden of allergic rhinitis amongst UK patients 75% reported some impact of their allergic rhinitis symptoms on health-related quality of life. Allergic rhinitis currently affects 10-30% of the world population with prevalence and impact continuing to increase. This leads to substantial economic costs both of prescription medication and time taken off work by both patients and carers due to the disease. In view of this, there may be a substantial need for improved therapy or management to ensure that patients with allergic rhinitis can carry out a normal lifestyle.

The proposed study will evaluate the unmet therapy need in seasonal rhinitis by examining the current medication requirements of patients who suffer from seasonal grass-pollen hay fever and determining whether current therapies are sufficient for managing rhinitis.

This study aims to evaluate the unmet therapy need in seasonal rhinitis by -

1. Examining and describing current medication requirements

2. Quantifying the extent of co-prescribing of multiple agents

3. Comparing the effectiveness of current prescription drugs for managing and controlling patient's seasonal rhinitis and using changes in treatment during the hay fever season to determine the effectiveness of current therapy options.

for managing and controlling seasonal rhinitis in primary care patients who suffer from seasonal grass-pollen hay fever.

Study Timeline

• Study Start: 2013-01
• Primary Completion: 2013-03
• Study Completion: 2013-03
• Status Verified: 2013-06
• Study First Submitted: 2013-06-07
• Study First Submitted QC: 2013-06-07
• Last Update Submitted: 2013-06-07
• Study First Posted: 2013-06-11
• Last Update Posted: 2013-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21203

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Asthma Patients - Exacerbations: Severe	10.12.12	b)Asthma related -; Hospital attendance/admission OR A \& E attendance; OR Out-of-hours attendance; GP consultations for asthma related tract infections; Acute use of oral steroids
Co-prescribing	31.11.12	The proportion of patients managed at the index prescription date with more than one class of therapy
Number of Consultations	10.12.12	Defined as a consultation where an allergic rhinitis read code or hay fever code is recorded during the hay fever season.
Costing Analysis	15.01.13	Descriptive analysis of costs at the first prescription and final prescription of the season. Comparing those who remain on same therapy and those who add therapy during the season.
Treatment Outcomes	10.12.12	For those patients who receive a prescription for a diagnosis of seasonal rhinitis/ hay fever. The following outcomes will be measured -; * Patients who remain on the same therapy; * Patients who change therapy within same therapy group; * Patients who add additional therapy from another therapy group
Asthma Patients - Exacerbations: Clinical	10.12.12	where exacerbation is defined as an occurrence of the following: a)Lower respiratory related : Hospital attendance/admission OR A \& E attendance; OR Out-of-hours attendance; * GP consultations for lower respiratory related tract infections; * Acute use of oral steroids .

Trial Locations

Locations (1)

Research in Real Life Ltd; 🇬🇧 Cambridge, United Kingdom